Skip to content
sellWeak cluster of 210b5-1 plan

Helen Torley sold $6.6M of HALO

PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 60,000 shares at an average of $110.18, traded Oct 6, 2026, filed Oct 8, 2026.

Warning score
23
Value
$6.6M
60,000 shares
Holdings after
767,780
-8% from before
From 52-week low
+78%
low $61.63, close $109.72
From 52-week high
-5%
high $115.22, as of Oct 6, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $6.6M at market
    +25
  • Share of holdings sold
    Sold 7.6% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HALOOct 9, 2026 · close 110.42
Since filing Oct 8, 2026: +0.5%SPY +0.6% · excess -0.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001159036-26-000140, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 6, 2026MOption exercise
Common Stock10b5-1
+20,000$18.41$368k787,7804 d ago
Oct 6, 2026SOpen-market sale
Common Stock10b5-1
-2,300$107.90$248k785,4804 d ago
Oct 6, 2026SOpen-market sale
Common Stock10b5-1
-6,000$109.33$656k779,4804 d ago
Oct 6, 2026SOpen-market sale
Common Stock10b5-1
-9,920$109.89$1.1M769,5604 d ago
Oct 6, 2026SOpen-market sale
Common Stock10b5-1
-1,780$110.81$197k767,7804 d ago
Oct 7, 2026MOption exercise
Common Stock10b5-1
+20,000$18.41$368k787,7804 d ago
Oct 7, 2026SOpen-market sale
Common Stock10b5-1
-8,600$111.03$955k779,1804 d ago
Oct 7, 2026SOpen-market sale
Common Stock10b5-1
-10,300$111.84$1.2M768,8804 d ago
Oct 7, 2026SOpen-market sale
Common Stock10b5-1
-900$112.78$102k767,9804 d ago
Oct 7, 2026SOpen-market sale
Common Stock10b5-1
-200$113.69$23k767,7804 d ago
Oct 8, 2026MOption exercise
Common Stock10b5-1
+20,000$18.41$368k787,7804 d ago
Oct 8, 2026SOpen-market sale
Common Stock10b5-1
-4,810$108.18$520k782,9704 d ago
Oct 8, 2026SOpen-market sale
Common Stock10b5-1
-3,090$108.91$337k779,8804 d ago
Oct 8, 2026SOpen-market sale
Common Stock10b5-1
-11,900$110.00$1.3M767,9804 d ago
Oct 8, 2026SOpen-market sale
Common Stock10b5-1
-200$110.51$22k767,7804 d ago
Oct 6, 2026MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$18.41$368k61,5524 d ago
Oct 7, 2026MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$18.41$368k41,5524 d ago
Oct 8, 2026MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$18.41$368k21,5524 d ago

Related signals

Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
22Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$568k
5,230 shares
-9%
33Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$2.0M
18,996 shares
-24%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.4M
60,000 shares
-8%
13Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Nicole LaBrosse
SVP, CHIEF FINANCIAL OFFICER
$174k
2,227 shares
-9%
37Weak
HALOsell 310b5-1
HALOZYME THERAPEUTICS, INC.
Nicole LaBrosse
SVP, CHIEF FINANCIAL OFFICER
$1.5M
20,000 shares
-45%
30Weak
HALOsell 310b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$4.4M
60,000 shares
-8%
24Weak
HALOsell 310b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$295k
4,000 shares
-8%
15Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.8M
60,000 shares
-8%
15Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.4M
60,000 shares
-8%
15Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.2M
60,000 shares
-8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Helen Torley sold $6.6M of HALO | InsiderTell